Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening
Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay. The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening. The Onclarity Self-Collection Kit...
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo